What is MOTS-c?
A 16-amino-acid peptide coded by a short stretch of mitochondrial DNA (in the 12S rRNA gene).
US legal status
Open question
Whether HHS has made the policy final after its comment period is not confirmed. We found no later Federal Register document on it.
Changes
What the human evidence looks like
What programs claim, and what has been studied
Safety facts
Reports to the FDA
- The FDA's own searches of FAERS, its adverse event database, up to March 9, 2025 found 0 reports, and an openFDA search (MOTS-C, MOTSC, MOTS C) also returns 0. The FDA notes that 503A compounders "generally do not report" adverse events, and zero reports is not evidence of safety.36
- USADA lists side effects "among people who claim to purchase MOTS-c online": fast heart rate or palpitations, irritation where it was injected, insomnia, immune reactions and fever. These are unverified reports passed on by USADA, not trial data.11
What the FDA has said
- The FDA found no human exposure data and no clinical safety studies, and says the "potential safety risks associated with the use of MOTS-c in humans are unknown."3
- The FDA named three concerns: immunogenicity (an immune response to the peptide, possibly against the body's own MOTS-c), aggregation and peptide-related impurities, "especially when administered by injection routes".35
- The FDA says MOTS-c is "quickly hydrolyzed in human blood" in a test tube, which "raises the question" whether it reaches active levels in the body.313
- Compounded drugs are not FDA-approved: the FDA doesn't review their safety, effectiveness or quality before they're sold.222
No data
- The FDA found no study of either form for acute toxicity, toxicity with repeated use, genotoxicity, effects on development and reproduction, or carcinogenicity.3
- The FDA found no carcinogenicity study of MOTS-c, and we found no FDA or NIH statement linking MOTS-c to cancer.3
- We found no data on pregnancy or breastfeeding, children, long-term use, people with cancer, or blends.3
Product quality
Compounded MOTS-c is prepared by a pharmacy to a prescription. It is not FDA-approved: the FDA doesn’t review its safety, effectiveness or quality before it’s sold.
You can report a side effect to the FDA through MedWatch.
What a trustworthy program shows
The conditions of the HHS policy
The policy covers a compounded product only when all of its conditions are met.
- 1.HHS notice of availability, FR Doc 2026-22192, 91 FR 68526 (Oct 30, 2026)Tier 1: regulator or registergovinfo.govread Nov 16, 2026↩
- 2.HHS enforcement discretion policy with Appendix A and B (Internet Archive copy of hhs.gov, Nov 15, 2026)Tier 1: regulator or registerweb.archive.orgread Nov 16, 2026↩
- 3.FDA briefing document: MOTS-c-related bulk drug substances (memo 5/11/2026), PCAC Jul 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 4.FDA: PCAC meeting page, Jul 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 5.FDA: Certain bulk drug substances that may present significant safety risks (Apr 22, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 6.openFDA FAERS search for MOTS-C, MOTSC, MOTS C (0 results)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 7.FDA: PCAC questions, Jul 23–24, 2026Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 8.ClinicalTrials.gov NCT07505745: MOTS-c in adults with prediabetes and overweight/obesityTier 1: regulator or registerclinicaltrials.govread Nov 16, 2026↩
- 9.ClinicalTrials.gov NCT03998514: CB4211 Phase 1a/1bTier 1: regulator or registerclinicaltrials.govread Nov 16, 2026↩
- 10.Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metab 2015;21(3):443-54Tier 1: regulator or registerpubmed.ncbi.nlm.nih.govread Nov 16, 2026
- 11.USADA: What is the MOTS-c peptide?Tier 1: regulator or registerusada.orgread Nov 16, 2026↩
- 12.FDA Law Blog (Hyman Phelps): PCAC approves four bulk drug substances (Jul 2026)Tier 3: reference, law firm or pressthefdalawblog.comread Nov 16, 2026↩
- 13.Knoop A et al. Mass spectrometry detection of MOTS-c in plasma for doping control. Rapid Commun Mass Spectrom 2019;33(4):371-80Tier 1: regulator or registerpubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 14.Reynolds JC et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator. Nat Commun 2021;12:470Tier 1: regulator or registerpmc.ncbi.nlm.nih.govread Nov 16, 2026↩
- 15.von Walden F et al. Acute endurance exercise stimulates circulating mitochondrial-derived peptides. J Appl Physiol 2021;131(3):1035-42Tier 1: regulator or registerpubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 16.Fuku N et al. MOTS-c: a player in exceptional longevity? Aging Cell 2015;14(6):921-3Tier 1: regulator or registerpubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 17.Zempo H et al. A pro-diabetogenic mtDNA polymorphism in MOTS-c. Aging 2021;13(2):1692-1717Tier 1: regulator or registerpubmed.ncbi.nlm.nih.govread Nov 16, 2026↩
- 18.PubMed searches: MOTS-c (total, humans, reviews, trial types, by year), CB4211Tier 1: regulator or registereutils.ncbi.nlm.nih.govread Nov 16, 2026↩
- 19.ClinicalTrials.gov API search "MOTS-c" (9 records)Tier 1: regulator or registerclinicaltrials.govread Nov 16, 2026
- 20.Drugs@FDA (openFDA) and DailyMed searches: MOTS-c (none), elamipretide (NDA 215244, Forzinity, approved Sep 19, 2025), retatrutide (none)Tier 1: regulator or registerapi.fda.govread Nov 16, 2026↩
- 21.FDA warning letter, www.usapeptide.com (Feb 26, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 22.FDA: Bulk drug substances used in compounding under section 503ATier 1: regulator or registerfda.govread Nov 16, 2026↩
- 23.FDA: Bulk drug substances nominated for use in compounding under section 503A (PDF, updated May 14, 2026)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 24.FDA: Bulk drug substances nominated for use in compounding under section 503B (PDF, updated Mar 21, 2025)Tier 1: regulator or registerfda.govread Nov 16, 2026↩
- 25.DEA: Controlled substances, alphabetical order (12-Nov-26)Tier 1: regulator or registerdeadiversion.usdoj.govread Nov 16, 2026↩
- 26.FDA warning letters: database search "MOTS-c" (0) and 15 letters to peptide or online-drug sellers, Feb 2025 to Sep 2026, read in fullTier 1: regulator or registerfda.govread Nov 16, 2026↩
- 27.Federal Register API: documents mentioning "MOTS-c" (1, the PCAC meeting notice of Apr 16, 2026) and "peptide compounding" since Oct 30, 2026 (only 2026-22192 relevant)Tier 1: regulator or registerfederalregister.govread Nov 16, 2026↩
We review programs, not peptides. This page reports what has been studied and what US regulators have said, with the source of each fact.
It is not medical advice: a decision about a medication is one to make with a licensed clinician.